Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 3, 2026World Journal of Gastrointestinal OncologyOpen Access

Shifting paradigm in locally advanced resectable gastric and gastroesophageal junction cancers

View Full Paper
Ask AI
Bookmark
Share

Authors

NINabil Ismaili

Discussion

Loading...

Member takes

Overview

Observational analysis uncovers improved outcomes with immunotherapy in gastric cancer, suggesting a new standard of care.

Key Points

  • Overall survival in gastric cancer improves significantly with the addition of immunotherapy to chemotherapy.
  • Patients treated with the perioperative sintilimab regimen showed a marked increase in pathological response rates.
  • Assessment using a real-world study design highlights the need for effective treatment alternatives in gastric cancer management.
  • This cumulative evidence suggests a potential shift in treatment standards pending further regulatory approvals.

Cite This Study

Nabil Ismaili (2026) studied this question.

synapsesocial.com/papers/69a7656dbadf0bb9e87d90f9https://doi.org/10.4251/wjgo.v18.i2.113150
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma2024 · 538 citations
  2. 2The Role of ctDNA in Gastric Cancer2022 · 49 citations
  3. 3Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer2025 · 230 citations